4507283 Pharmacologically active compounds

256

PATENT

ABSTRACTS

Healthcare Products r ix;

4507281 INTERFERON-CONTAINING COMPOSITIONS Samuel S Asculai, Fred Rapp assigned to Exovir Inc A composition for treating herpes simplex viral infections in humans is disclosed, comprising about 102 to 108 I.U. of human interferon, about 0. I% to 20% by weight of an antiviral surface active agent, and a physiologically acceptable carrier. Most preferably, the composition comprises about 104 to 106 I.U. of human leukocyte interferon, about I'% to 5 ~ by weight o f a nonionic surface active agent having at least one ether or amide linkage, and a physiologically acceptable carrier. A method for treating herpes simplex viral infections in humans is also disclosed, comprising topically administering an effective amount of said antiherpetic composition to the affected area. Most preferably, an effective amount of said antiherpetic composition is topically administered to the affected area during the prodromal stage of viral multiplication.

4507283 PHARMACOLOGICALLY COMPOUNDS

ACTIVE

Richard A G Smith, Reigate, United Kingdom assigned to Beecham G r o u p p I c A derivative of streptokinase-human plasminogen activator complex, in which the active catalytic site essential for fibrinolytic activity is blocked by a 2- or 4-aminobenzoyl group, is useful in treating venous thrombosis. The blocking group is removable by hydrolysis such that the first order rate is in the range 0.7*10-5sec-I to 2.5*10-5sec-I in isotonic aqueous media at pH 7.4 at 37 degrees C.

Mouse monoclonal antibody AbR24 (Dippold et al., Proc. Natl. Acad. Sci. 77:6114-6118, 1980) has a high degree of specificity for human melanoma cells when tested on viable cultured cells using the P A - M H A serological assay. The antigen detected by this antibody has been isolated from melanoma cells and shown to be GD3 ganglioside by compositional and partial structural analysis and by comparison with authentic GD3 by thin layer chromatography (TLC). AbR24 reacts with authentic GD3, but not with any other ganglioside tested. Using TLC and reactivity with AbR24, a wide range of cells and tissues was examined for the presence of GD3. A new serological assay, termed glycolipid-mediated immune adherence (GMIA), was devised for assaying the reactivity of AbR24 with gangliosides. Melanomas (cultured cells or tumor tissue) were shown to have TD3 and G M 3 as major gangliosides. Other cells and tissues examined also contained GD3, but usually only in low amounts. Melanomas (and MOLT-4, a T-cell line) were characterized by a simplified ganglioside profile with G D 3 and GM3 as major components. The apparent discrepancy between the ubiquitous presence of GD3 and the serological specificity of AbR24 for melanoma cells can be explained in terms of localization and concentration of G D 3 in different cells.

4508643 RAT ANTIBODY

TO HCG

Edward G Calamai, Martha A Daigle assigned to Baxter Travenol Laboratories lnc Antibody against human chorionic gonadotropin is raised in rats, preferably Lewis Strain Inbred rats, using either whole hormone or the beta-subunit as the antigen, and displays low cross-reactivity with luteinizing hormone as well as high sensitivity.

4507391 4508647 METHOD FOR DETECTING PRESENCE OF GD3 GANGLIOSIDE

THE

Clifford S Pukel, Kenneth 0 Lloyd. Luiz R Travassos, Wolfgang Dippold, Herbert Oettgen. Lloyd J Old assigned to Sloan-Kettering Institute for Cancer Research

ANTITUMOR ANTIBIOTICS BBM-2040A AND BBM-2040B Masami HatorL Hiroak Ohkuma. Masataka Konishi. Takco Miyaki. Hiroshi Kav, aguchi. Yokosuka, Japan assigned to Bristol-Myers Company